Obesity Clinical Trials in Little Rock, Arkansas

8 studies are recruiting for obesity in Little Rock, Arkansas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

   This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Arkansas Cardiology, Little Rock, Arkansas

   Locations

   657 in total

   Run by

   Amgen

   See if you can join NCT07037459 on ClinicalTrials.gov

2. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

   Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-2 Clinical Site, Little Rock, Arkansas

   Locations

   135 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743450 on ClinicalTrials.gov

3. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

   Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-1 Clinical Site, Little Rock, Arkansas

   Locations

   122 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743463 on ClinicalTrials.gov

4. Level Up! (The Combined and Independent Effects of Exercise Training and Dietary Enhancement on Cardiometabolic Health in Adolescents With Obesity)

   The goal of this clinical trial is to learn how exercise and diet quality affect the health of adolescents with obesity. The main questions it aims to answer are: * Does exercise improve cardiometabolic health in adolescents with obesity? * Does enriching the diet with fruits and vegetables improve…

   Stage

   Not phased

   Ages

   13 to 17

   Site

   Arkansas Children's Hospital Research Institute, Little Rock, Arkansas

   Locations

   2 in total

   Run by

   Arkansas Children's Hospital Research Institute

   See if you can join NCT06848478 on ClinicalTrials.gov

5. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

   This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-2 Research Site, Little Rock, Arkansas

   Locations

   74 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654374 on ClinicalTrials.gov

6. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

   The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Kailera Clinical Site, Little Rock, Arkansas

   Locations

   59 in total

   Run by

   Kailera

   See if you can join NCT07284979 on ClinicalTrials.gov

7. A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

   This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Arkansas Clinical Research, Little Rock, Arkansas

   Locations

   303 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07564414 on ClinicalTrials.gov

8. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Arkansas Health Group, Little Rock, Arkansas

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov